Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today its interim financial results for the three month period ended November 30, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system for the disclosure documents of issuers across Canada, at www.SEDAR.com.
The reported period included the submission of Investigational New Drug (“IND”) applications to the US Food and Drug Administration (“FDA”) for two Phase 2a studies in fibromyalgia and binge eating disorder with the University of Michigan and the University of Florida, respectively, that were subsequently authorized by the FDA to proceed.
The Company’s total assets as of November 30, 2021 were $2.4 million, including $2.1 million in cash. Net and comprehensive losses for the three months ended November 30, 2021 were both $3.0 million.
